文献速递传染病防控与疫情报告免疫规划

建立豚鼠吸入性炭疽模型以评估炭疽疫苗暴露后预防效果

Development of a guinea pig inhalational anthrax model for evaluation of post-exposure prophylaxis efficacy of anthrax vaccines.
PubMed 文献 · Vaccine · 2020-02-03

研究建立豚鼠吸入性炭疽暴露后预防模型,先确定环丙沙星部分治愈方案(7.5 mg/kg 腹腔注射每日三次、暴露后1天开始连用14天),再评估AV7909疫苗联合该方案的效果;结果显示联合AV7909疫苗较单用环丙沙星显著提高豚鼠生存率,提示该模型可用于展示疫苗的附加价值。

要点

  • 豚鼠吸入性炭疽模型中,环丙沙星7.5 mg/kg腹腔注射每日三次、暴露后1天起连用14天为耐受良好的部分治愈方案。
  • 环丙沙星治疗豚鼠暴露后1天和8天接种AV7909系列稀释液、AVA 1:16稀释液或生理盐水。
  • AV7909联合部分治愈环丙沙星方案较单用环丙沙星显著提高豚鼠生存率。

核心结论

  • 结果表明所建立的模型可用于展示疫苗在暴露后预防中的附加价值。

研究设计与样本

  • 研究建立豚鼠吸入性炭疽暴露后预防模型,先评估暴露后环丙沙星药代动力学、耐受性和生存。
  • 在部分治愈环丙沙星方案基础上评估AV7909疫苗的附加获益,设未治疗阳性对照组以确认致死性炭疽芽孢杆菌暴露。

主要发现

  • 环丙沙星7.5 mg/kg腹腔注射每日三次、暴露后1天开始连用14天为耐受良好的部分治愈方案。
  • 环丙沙星治疗豚鼠于暴露后1天和8天接种AV7909系列稀释液、AVA 1:16稀释液或生理盐水。
  • 暴露后接种AV7909联合部分治愈环丙沙星方案较单用环丙沙星显著提高豚鼠生存率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A next-generation anthrax vaccine candidate, AV7909, is being developed for post-exposure prophylaxis (PEP) of inhalational anthrax in combination with the recommended course of antimicrobial therapy. Clinical efficacy studies of anthrax countermeasures in humans are not ethical or feasible, therefore, licensure of AV7909 for PEP is being pursued under the US Food and Drug Administration (FDA) Animal Rule, which requires that evidence of effectiveness be demonstrated in an animal model of anthrax, where results of studies in such a model can establish reasonable likelihood of AV7909 to produce clinical benefit in humans. Initial development of a PEP model for inhalational anthrax included evaluation of post-exposure ciprofloxacin pharmacokinetics (PK), tolerability and survival in guinea pigs treated with various ciprofloxacin dosing regimens. Three times per day (TID) intraperitoneal (IP) dosing with 7.5 mg/kg of ciprofloxacin initiated 1 day following inhalational anthrax challenge and continued for 14 days was identified as a well tolerated partially curative ciprofloxacin treatment regimen. The added benefit of AV7909 vaccination was evaluated in guinea pigs given the partially curative ciprofloxacin treatment regimen. Groups of ciprofloxacin-treated guinea pigs were vaccinated. 1 and 8 days post-challenge with serial dilutions of AV7909, a 1:16 dilution of AVA, or normal saline. A group of untreated guinea pigs was included as a positive control to confirm lethal B. anthracis exposure. Post-exposure vaccination with the AV7909 anthrax vaccine candidate administered in combination with the partially curative ciprofloxacin treatment significantly increased survival of guinea pigs compared to ciprofloxacin treatment alone. These results suggest that the developed model can be useful in demonstrating added value of the vaccine for PEP.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Perry MR, Ionin B, Barnewall RE, et al. Development of a guinea pig inhalational anthrax model for evaluation of post-exposure prophylaxis efficacy of anthrax vaccines. Vaccine. 2020. PMID: 32029323. doi:10.1016/j.vaccine.2020.01.068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。